<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Ucb S.a. — News on 6ix</title>
<link>https://6ix.com/company/ucb-sa-1</link>
<description>Latest news and press releases for Ucb S.a. on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Fri, 27 Mar 2026 06:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/ucb-sa-1" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo69d68fd8beedb30cb6ff00c7.webp</url>
<title>Ucb S.a.</title>
<link>https://6ix.com/company/ucb-sa-1</link>
</image>
<item>
<title>UCB - Convening Notice to the General Meeting of the Shareholders 2026</title>
<link>https://6ix.com/company/ucb-sa-1/news/ucb-convening-notice-to-the-general-meeting-of-the-shareholders-2026</link>
<guid isPermaLink="true">https://6ix.com/company/ucb-sa-1/news/ucb-convening-notice-to-the-general-meeting-of-the-shareholders-2026</guid>
<pubDate>Fri, 27 Mar 2026 06:00:00 GMT</pubDate>
<description>CONVENING NOTICE TO THE GENERAL MEETING OF SHAREHOLDERS The Board of Directors invites the shareholders to the general meeting of the shareholders (the “General Meeting”) which will be held on Thursday, 30 April 2026, at 11:00 am CEST, at the registered office of UCB SA/NV, Allée de la Recherche 60 - 1070 Brussels, for the purpose of considering and voting on the items shown on the agenda set out below. Applicable participation formalities are detailed at the end of this convening notice. Shareh</description>
</item>
<item>
<title>Gen Z and Millennial Patients with Chronic Rheumatic Diseases Are Opening Up to Raise Awareness for Improved Care</title>
<link>https://6ix.com/company/ucb-sa-1/news/gen-z-and-millennial-patients-with-chronic-rheumatic-diseases-are-opening-up-to-raise-awareness-for-improved-care</link>
<guid isPermaLink="true">https://6ix.com/company/ucb-sa-1/news/gen-z-and-millennial-patients-with-chronic-rheumatic-diseases-are-opening-up-to-raise-awareness-for-improved-care</guid>
<pubDate>Wed, 10 Sep 2025 12:00:00 GMT</pubDate>
<description>UCB, a global biopharmaceutical company, today shared results from the "Rheum for Improvement" survey that sought to further understand unmet needs among patients living with psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA), which includes both non-radiographic axial spondyloarthritis (nr-axSpA) and ankylosing spondylitis (AS).</description>
</item>
<item>
<title>UCB presents latest research and clinical advancement across leading epilepsy portfolio at International Epilepsy Congress</title>
<link>https://6ix.com/company/ucb-sa-1/news/ucb-presents-latest-research-and-clinical-advancement-across-leading-epilepsy-portfolio-at-international-epilepsy-congress</link>
<guid isPermaLink="true">https://6ix.com/company/ucb-sa-1/news/ucb-presents-latest-research-and-clinical-advancement-across-leading-epilepsy-portfolio-at-international-epilepsy-congress</guid>
<pubDate>Fri, 29 Aug 2025 06:00:00 GMT</pubDate>
<description>UCB, a global biopharmaceutical company, today announced it will present 26 abstracts from its epilepsy portfolio at the International Epilepsy Congress (IEC) Congress, Lisbon, Portugal, August 30 – September 3, 2025. Data will focus on developmental and epileptic encephalopathies (DEEs), such as Dravet syndrome (DS) and Lennox-Gastaut syndrome (LGS), as well as prolonged seizures, seizure emergencies and early pipeline research.</description>
</item>
<item>
<title>UCB's HS Summit United Patients and Experts to Drive Progress in Hidradenitis Suppurativa Awareness and Treatment</title>
<link>https://6ix.com/company/ucb-sa-1/news/ucbs-hs-summit-united-patients-and-experts-to-drive-progress-in-hidradenitis-suppurativa-awareness-and-treatment</link>
<guid isPermaLink="true">https://6ix.com/company/ucb-sa-1/news/ucbs-hs-summit-united-patients-and-experts-to-drive-progress-in-hidradenitis-suppurativa-awareness-and-treatment</guid>
<pubDate>Tue, 05 Aug 2025 12:00:00 GMT</pubDate>
<description>UCB, a global biopharmaceutical company, hosted its 2025 Hidradenitis Suppurativa (HS) Summit, which aimed to create a community forum for open discussion about HS, a dermatologic disease that remains both underdiagnosed and often misdiagnosed.2-3 By bringing stakeholders together, UCB sought to foster a deeper understanding of HS and address the challenges associated with it.</description>
</item>
<item>
<title>UCB extends its BIMZELX® "Get Yourself Back" direct-to-consumer campaign for the hidradenitis suppurativa community</title>
<link>https://6ix.com/company/ucb-sa-1/news/ucb-extends-its-bimzelxr-get-yourself-back-direct-to-consumer-campaign-for-the-hidradenitis-suppurativa-community</link>
<guid isPermaLink="true">https://6ix.com/company/ucb-sa-1/news/ucb-extends-its-bimzelxr-get-yourself-back-direct-to-consumer-campaign-for-the-hidradenitis-suppurativa-community</guid>
<pubDate>Tue, 08 Jul 2025 11:00:00 GMT</pubDate>
<description>UCB, a global biopharmaceutical company, today announced the expansion of its "Get Yourself Back" direct-to-consumer (DTC) advertising campaign for BIMZELX® (bimekizumab-bkzx). This campaign aims to raise awareness of BIMZELX and offers educational resources about both BIMZELX and hidradenitis suppurativa (HS), encouraging people living with the disease to talk with their healthcare provider about whether BIMZELX is right for them. BIMZELX is the first and only approved treatment for adults with</description>
</item>
<item>
<title>UCB announces positive results from GEMZ Phase 3 study of fenfluramine in CDKL5 deficiency disorder</title>
<link>https://6ix.com/company/ucb-sa-1/news/ucb-announces-positive-results-from-gemz-phase-3-study-of-fenfluramine-in-cdkl5-deficiency-disorder</link>
<guid isPermaLink="true">https://6ix.com/company/ucb-sa-1/news/ucb-announces-positive-results-from-gemz-phase-3-study-of-fenfluramine-in-cdkl5-deficiency-disorder</guid>
<pubDate>Fri, 27 Jun 2025 11:00:00 GMT</pubDate>
<description>UCB, a global biopharmaceutical company, today announced that the Phase 3 study investigating the safety and efficacy of adjunctive fenfluramine in CDKL5 deficiency disorder (CDD) met its primary and most key secondary endpoints.3 The study is a randomized, double-blind, placebo-controlled, fixed-dose, multi-center study examining the efficacy and safety of adjunctive fenfluramine treatment in 87 individuals aged one through 35, with a CDD diagnosis and uncontrolled seizures.4</description>
</item>
<item>
<title>UCB presents latest thymidine kinase 2 deficiency (TK2d) research at the United Mitochondrial Disease Foundation (UMDF) 2025 Conference</title>
<link>https://6ix.com/company/ucb-sa-1/news/ucb-presents-latest-thymidine-kinase-2-deficiency-tk2d-research-at-the-united-mitochondrial-disease-foundation-umdf-2025-conference</link>
<guid isPermaLink="true">https://6ix.com/company/ucb-sa-1/news/ucb-presents-latest-thymidine-kinase-2-deficiency-tk2d-research-at-the-united-mitochondrial-disease-foundation-umdf-2025-conference</guid>
<pubDate>Fri, 20 Jun 2025 11:00:00 GMT</pubDate>
<description>UCB, a global biopharmaceutical company, announced it will present pioneering TK2d research at the UMDF Mitochondrial Medicine 2025 Conference taking place June 18-21, 2025, in St. Louis, Missouri.</description>
</item>
<item>
<title>Inaugural 2025 UCB U.S. Myasthenia Gravis Scholarship™ grants 15 scholarships to people impacted by myasthenia gravis in the U.S.</title>
<link>https://6ix.com/company/ucb-sa-1/news/inaugural-2025-ucb-us-myasthenia-gravis-scholarshiptm-grants-15-scholarships-to-people-impacted-by-myasthenia-gravis-in-the-us</link>
<guid isPermaLink="true">https://6ix.com/company/ucb-sa-1/news/inaugural-2025-ucb-us-myasthenia-gravis-scholarshiptm-grants-15-scholarships-to-people-impacted-by-myasthenia-gravis-in-the-us</guid>
<pubDate>Tue, 17 Jun 2025 12:22:00 GMT</pubDate>
<description>UCB, a global biopharmaceutical company, today announced that 15 scholarships were awarded to people impacted by myasthenia gravis in the U.S. The UCB Myasthenia Gravis Scholarship™ exemplifies UCB's dedication to supporting the rare disease community that goes beyond medicine. Living with or supporting a loved one impacted by this rare disease can be challenging. This scholarship program can help ease the costs associated with education and allow recipients to gain new skills to further their c</description>
</item>
<item>
<title>UCB Announces Major U.S. Investment to Expand Biologics Manufacturing Capacity</title>
<link>https://6ix.com/company/ucb-sa-1/news/ucb-announces-major-us-investment-to-expand-biologics-manufacturing-capacity</link>
<guid isPermaLink="true">https://6ix.com/company/ucb-sa-1/news/ucb-announces-major-us-investment-to-expand-biologics-manufacturing-capacity</guid>
<pubDate>Thu, 12 Jun 2025 16:30:00 GMT</pubDate>
<description>UCB, a global biopharmaceutical company focused on improving the lives of people with severe diseases, today announced plans for a significant investment in a new, state-of-the-art biologics manufacturing facility in the United States. The project is expected to serve UCB's growing number of patients in the U.S., while delivering a total estimated economic impact of approximately $5 billion. UCB is also continuing to scale up its partnerships with U.S. CMOs to ensure the support for the producti</description>
</item>
<item>
<title>BIMZELX® (bimekizumab-bkzx) Three-Year Data at EULAR 2025 Showed Lasting Efficacy and Control of Inflammation in Psoriatic Arthritis and Axial Spondyloarthritis</title>
<link>https://6ix.com/company/ucb-sa-1/news/bimzelxr-bimekizumab-bkzx-three-year-data-at-eular-2025-showed-lasting-efficacy-and-control-of-inflammation-in-psoriatic-arthritis-and-axial-spondyloarthritis</link>
<guid isPermaLink="true">https://6ix.com/company/ucb-sa-1/news/bimzelxr-bimekizumab-bkzx-three-year-data-at-eular-2025-showed-lasting-efficacy-and-control-of-inflammation-in-psoriatic-arthritis-and-axial-spondyloarthritis</guid>
<pubDate>Wed, 11 Jun 2025 16:16:00 GMT</pubDate>
<description>UCB, a global biopharmaceutical company, today announced new three-year data from Phase 3 trials, and their open-label extensions, investigating BIMZELX® (bimekizumab-bkzx) in adults with active psoriatic arthritis (PsA) and active axial spondyloarthritis (axSpA), which includes both non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation and ankylosing spondylitits (AS). BIMZELX, a dual inhibitor of IL-17A and IL-17F,1 demonstrated sustained control of inflammat</description>
</item>
<item>
<title>UCB and Domino Data Lab Collaborate to Modernize Statistical Computing Environment in Life Sciences</title>
<link>https://6ix.com/company/ucb-sa-1/news/ucb-and-domino-data-lab-collaborate-to-modernize-statistical-computing-environment-in-life-sciences</link>
<guid isPermaLink="true">https://6ix.com/company/ucb-sa-1/news/ucb-and-domino-data-lab-collaborate-to-modernize-statistical-computing-environment-in-life-sciences</guid>
<pubDate>Mon, 19 May 2025 16:30:00 GMT</pubDate>
<description>UCB, a global biopharmaceutical company, and Domino Data Lab, provider of a leading data science platform trusted by the world's largest enterprises, today announced a strategic collaboration aimed at modernizing a Statistical Computing Environment (SCE) for the life sciences industry. This joint effort aims to transform the legacy SCE into unified, scalable, and flexible platforms to meet the evolving demands of clinical research, regulatory compliance, and efficient data analysis.</description>
</item>
</channel>
</rss>